Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05207033 · ClinicalTrials.gov registry record · NA
Responses to Regulated E-Cigarette Advertisements
A NA study of Tobacco Use, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- NA
- Development phase
- 195
- Enrollment target
- 1
- Study location
NCT05207033: Completed NA study of Tobacco Use, sponsored by University of Massachusetts, Worcester.
NCT05207033 is a NA study of Tobacco Use that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 195 participants, below the 376-participant average among 76 other Tobacco Use trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05207033, a NA study of Tobacco Use, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- NA
- Development phase
- 195 participants
- Enrollment target
- 1
- Study location
Study Summary
While conventional cigarette use continues to decline among youth and young adults, e-cigarette (EC) use is on the rise. Specifically, the investigators will conduct a randomized control trial (RCT) where young adults are randomized to one of two conditions: 1) a regulated ad environment, with high impact EC ad features removed or 2) an unregulated ad environment, with high impact EC ad features left intact. Participants will view EC ads embedded in an online magazine 24 times over the course of 6 months. EC experimentation and sustained use will be the primary outcome of interest.
Primary Outcome
Use of any tobacco products
Conditions Studied
Interventions
- OTHER Regulated ad condition
- OTHER Unregulated ad condition
Study Locations (1)
Massachusetts
- UMass Chan Medical School Stevens Lab - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2024-07-01 |
| Phase | NA |
What the finished NCT05207033 record still lists
NCT05207033 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 76 other Tobacco Use trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Tobacco Use appearing as the primary indexed condition, and to 2 interventions - of which Regulated ad condition is the first listed.
NCT05207033 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05207033 about?
NCT05207033 is a clinical study titled "Responses to Regulated E-Cigarette Advertisements". While conventional cigarette use continues to decline among youth and young adults, e-cigarette (EC) use is on the rise. Specifically, the investigators will conduct a randomized control trial (RCT) where young adults are randomized to one of two conditions: 1) a regulated ad environment, with high ...
What is the current status of trial NCT05207033?
This trial is currently completed. It is a NA study. The enrollment target is 195 participants. The study started on 2022-04-01. Estimated completion is 2024-07-01.
What conditions does trial NCT05207033 study?
This clinical trial studies the following conditions: Tobacco Use.
What interventions are being tested in trial NCT05207033?
The interventions under investigation include: Regulated ad condition (OTHER), Unregulated ad condition (OTHER).
Who is sponsoring clinical trial NCT05207033?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05207033 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05207033's enrollment target sits among peer trials
195 28th of 76 higher than 49 of 76 other Tobacco Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
RECRUITING · NA
-
Opioids, Low Nicotine Cigarettes, and Chronic Pain
RECRUITING · NA
-
Reach Through Equitable Implementation in Utah
RECRUITING · NA
-
RTMS Targets Neural Circuits for Smoking Cessation
RECRUITING · NA
-
Cigar Legislation and Regulation in Tobacco for the Young (Project CLARITY)
RECRUITING · NA
-
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI